Clinical trial
Venlafaxine Augmentation in Treatment Resistant Depression
NCT00253266 · Max-Planck-Institute of Psychiatry, Other · Completed
Key facts
| NCT number | NCT00253266 |
|---|---|
| Title | Venlafaxine Augmentation in Treatment Resistant Depression |
| Official title | Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression |
| Lead sponsor | Max-Planck-Institute of Psychiatry, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Venlafaxine, Quetiapine |
| Enrollment | 126 |
| Start date | Apr 1, 2008 |
| Primary completion | Apr 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 8, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: